1. SARS-CoV-2 treatment effects induced by ACE2-expressing microparticles are explained by the oxidized cholesterol-increased endosomal pH of alveolar macrophages.
- Author
-
Wang Z, Lv J, Yu P, Qu Y, Zhou Y, Zhou L, Zhu Q, Li S, Song J, Deng W, Gao R, Liu Y, Liu J, Tong WM, Qin C, and Huang B
- Subjects
- A549 Cells, Angiotensin-Converting Enzyme 2 genetics, Animals, COVID-19 virology, Chlorocebus aethiops, Disease Models, Animal, Female, Humans, Hydrogen-Ion Concentration, Lysosomes chemistry, Mice, Mice, Inbred ICR, Mice, Transgenic, Oxidation-Reduction, RAW 264.7 Cells, Treatment Outcome, Vero Cells, Angiotensin-Converting Enzyme 2 administration & dosage, Angiotensin-Converting Enzyme 2 metabolism, COVID-19 metabolism, COVID-19 therapy, Cell- and Tissue-Based Therapy methods, Cell-Derived Microparticles metabolism, Cholesterol metabolism, Endosomes chemistry, Macrophages, Alveolar metabolism, SARS-CoV-2 metabolism
- Abstract
Exploring the cross-talk between the immune system and advanced biomaterials to treat SARS-CoV-2 infection is a promising strategy. Here, we show that ACE2-overexpressing A549 cell-derived microparticles (AO-MPs) are a potential therapeutic agent against SARS-CoV-2 infection. Intranasally administered AO-MPs dexterously navigate the anatomical and biological features of the lungs to enter the alveoli and are taken up by alveolar macrophages (AMs). Then, AO-MPs increase the endosomal pH but decrease the lysosomal pH in AMs, thus escorting bound SARS-CoV-2 from phago-endosomes to lysosomes for degradation. This pH regulation is attributable to oxidized cholesterol, which is enriched in AO-MPs and translocated to endosomal membranes, thus interfering with proton pumps and impairing endosomal acidification. In addition to promoting viral degradation, AO-MPs also inhibit the proinflammatory phenotype of AMs, leading to increased treatment efficacy in a SARS-CoV-2-infected mouse model without side effects. These findings highlight the potential use of AO-MPs to treat SARS-CoV-2-infected patients and showcase the feasibility of MP therapies for combatting emerging respiratory viruses in the future., (© 2021. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF